Analyst Price Targets — FENC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 8, 2026 10:30 pm | — | Piper Sandler | $18.00 | $7.58 | TheFly | Fennec initiated with an Overweight at Piper Sandler |
| August 15, 2025 1:03 pm | Chase Knickerbocker | Craig-Hallum | $14.00 | $8.54 | TheFly | Fennec price target raised to $14 from $13 at Craig-Hallum |
| May 15, 2024 8:57 am | Chase Knickerbocker | Craig-Hallum | $17.00 | $7.34 | TheFly | Fennec price target lowered to $17 from $20 at Craig-Hallum |
| May 15, 2024 7:22 am | Raghuram Selvaraju | H.C. Wainwright | $15.00 | $7.03 | StreetInsider | Fennec Pharmaceuticals Inc. (FENC) PT Lowered to $15 at H.C. Wainwright |
| April 4, 2024 6:11 am | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $10.77 | TheFly | Fennec price target raised to $18 from $17 at H.C. Wainwright |
| March 19, 2024 9:31 am | Chase Knickerbocker | Craig-Hallum | $18.00 | $11.01 | StreetInsider | Fennec Pharmaceuticals Inc. (FENC) PT Raised to $18 at Craig-Hallum |
| November 22, 2022 8:25 am | — | Cantor Fitzgerald | $12.00 | $9.17 | Benzinga | Cantor Fitzgerald Upgrades Fennec Pharmaceuticals to Overweight, Raises Price Target to $12 |
| September 26, 2022 10:01 am | — | Wedbush | $19.00 | $7.11 | Benzinga | Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $19 |
Latest News for FENC
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~
Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to
RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on March 17, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 377,500 of the Company's common shares to 24…
Adherex Technologies (NASDAQ: FENC - Get Free Report) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of $0.0423 per share and revenue of $14.7490 million for the quarter. Individuals can check the company's upcoming Q4 2025 earning summary page for
San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fennec Pharmaceuticals Inc. (NASDAQ: FENC). The investigation focuses on Fennec Pharmaceuticals executive officers and whether investor losses may be recovered under federal securities laws.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FENC.
U.S. House Trading
No House trades found for FENC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.